A pattern I’ve been tracking across my patient panel for years: the person with schizophrenia or schizoaffective disorder who also carries a trauma history that nobody is treating. They arrive with auditory hallucinations that are, on closer listening, deeply intertwined with what happened to them, abuse, violence, coercive psychiatric experiences, and the standard clinical response has been to stabilize the psychosis pharmacologically and leave the trauma alone. Not because the trauma doesn’t matter. Because the field had quietly agreed that trauma-focused psychotherapy was too dangerous to attempt in this population. The assumption was that re-engaging traumatic material in a person with active psychosis risked decompensation, relapse, or worse. So the trauma sat there, untreated, fueling the very symptoms we were trying to suppress with antipsychotics.
This month, the Lancet Psychiatry published the STAR trial results, and that clinical consensus deserves serious reconsideration. The multicentre, pragmatic, randomised trial conducted across five UK National Health Service mental health Trusts enrolled 305 participants with co-occurring psychosis and PTSD, the very population most protocols have historically excluded, and tested an integrated approach: Trauma-Focused Cognitive Behaviour Therapy for psychosis, or TF-CBTp, layered onto treatment as usual. The safety signal was clear. No serious adverse events attributable to the therapy. Dropout rates did not differ meaningfully from what you see in single-diagnosis CBT trials. And the efficacy data showed the intervention worked.
A Population Hidden in Plain Sight
The prevalence numbers alone should have been driving urgency here. A UK secondary care study found that 38% of patients with a psychotic disorder met DSM-5 criteria for a provisional PTSD diagnosis, with another 37% meeting criteria for sub-threshold PTSD. That means across a typical community mental health caseload, you are looking at a significant portion of the psychosis population carrying untreated trauma that standard care plans don’t formally address. In my own practice, treating patients across addiction psychiatry and serious mental illness, this overlap is not a subgroup. It is the norm, particularly in underserved communities where trauma exposure is compounded by systemic adversity, incarceration, housing instability, and substance use.
The neuropharmacology of why this matters is worth stating directly. Trauma and psychosis share dysregulated threat-processing circuitry, hyperactive stress-response systems, disrupted hippocampal memory consolidation, and prefrontal inhibition failures that look remarkably similar whether the presenting diagnosis is PTSD or schizophrenia. When both are present simultaneously, they amplify each other. Antipsychotics can blunt the positive symptom burden, but they do nothing to the traumatic memory structures that keep the threat-response system lit. That’s the mechanistic case for integrated treatment, and it’s why the STAR trial’s design, combining trauma-focused work with CBT techniques adapted for psychosis, made theoretical sense before the data even came in.
Having treated thousands of patients with treatment-resistant presentations across mood and psychotic disorders, I can say the hesitancy to engage trauma in this population has been partly clinical and partly cultural. Clinicians worry, reasonably, about precipitating a psychotic episode. But the STAR data suggest the risk calculus has been miscalibrated. The intervention was not only tolerated, it was, by the trial’s own characterization, highly acceptable to participants. That matters. Acceptability in a population that has often experienced coercive or dismissive psychiatric care is not a soft endpoint.
What Trial Designers Have Been Getting Wrong
The exclusion of psychosis patients from trauma-focused trials has not been a minor oversight. It has been a structural choice that accumulated across decades of protocol design, shaping what we know and don’t know about how to treat one of psychiatry’s most prevalent comorbidities. The STAR protocol itself was designed explicitly to challenge this pattern, making it the largest multisite RCT of its kind to date for this population. That it took until 2026 to have this data in a flagship journal reflects how entrenched the exclusion assumption had become.
For trial designers working in the PTSD space, the design implication here is straightforward: blanket exclusion of participants with psychotic disorders is no longer defensible on safety grounds. The STAR trial ran across five NHS Trusts under pragmatic, real-world conditions, not a highly controlled academic environment with intensive safety monitoring available only at tertiary centers. These were community mental health patients. The protocol survived contact with clinical reality. Any future trauma-focused trial that excludes psychosis patients without a specific mechanistic rationale for doing so is building in a gap that will take another decade to close.
The endpoint architecture also warrants scrutiny. PTSD symptom scales validated in single-diagnosis populations may not fully capture the treatment response in someone whose traumatic re-experiencing is entangled with paranoid ideation or voices. The field needs psychosis-adapted outcome measures that can track improvement across both symptom domains simultaneously, rather than borrowing instruments designed for a population that didn’t look like this one.
The Signal Worth Watching
For the patients I see who sit precisely at this intersection, the person whose psychotic symptoms have been partially stabilized on a second-generation antipsychotic but whose trauma has never been touched, the STAR results represent something the field has needed to say clearly: withholding psychological intervention from this population has not been protecting them. It has been denying them treatment they can tolerate and benefit from.
What I’m watching next is whether NICE updates its psychosis guideline to incorporate TF-CBTp as a recommended intervention for this comorbidity, and whether US trial sponsors begin revising exclusion criteria in active PTSD protocol development. The data to justify that revision now exists. The question is how long it takes the infrastructure of trial design to catch up to what the evidence is actually showing.
References
- Lancet Psychiatry: “Trauma-focused therapy integrated with cognitive behavioural therapy for psychosis for people with post-traumatic stress disorder and psychosis (the STAR trial)”
- Neuroscience News: “STAR trial: TF-CBTp for co-occurring psychosis and PTSD, 305 participants enrolled”
- Psychiatric Services: “38% of UK secondary care psychosis patients meet DSM-5 criteria for PTSD”
- White Rose Research Online: STAR trial protocol: “Multisite randomised controlled trial of trauma-focused CBT for psychosis”
- PubMed: STAR trial primary results, adverse events and dropout data, June 2026
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
